BMRN up +3.68% percent Today $BMRN High is at 88.2
Post# of 106
Posted On: 11/10/2014 12:23:06 PM
BMRN up +3.68% percent Today $BMRN High is at 88.23 and the Low 85.78 with current volume of 607,844.
Recent News posted below.
Biomarin Pharmaceutical Inc BMRN other info.
http://investorshangout.com/Biomarin-Pharmace...MRN-53520/
BMRN Biomarin Pharmaceutical Inc Recent Headline News
Upgrade Alert for BioMarin Pharmaceutical (BMRN)
Comtex SmarTrend(R) - Mon Nov 10, 7:56AM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded from Neutral to Buy at Goldman Sachs today. The stock closed yesterday at $83.91 on volume of 727,000 shares, below average daily volume of 1.2 million. In the past 52 weeks, shares of BioMarin Pharmaceutical have traded between a low of $55.04 and a high of $86.80 and closed yesterday at $83.91, which is 52% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.8% while the 200-day MA has risen 0.4%.
BMRN: 86.64 (+2.73)
Shares of BMRN Up 13.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 05, 10:01AM CST
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on October 21st, 2014 at $73.58. In approximately 2 weeks, BioMarin Pharmaceutical has returned 13.66% as of today's recent price of $83.63.
BMRN: 86.64 (+2.73)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 92.60 (+1.54), VRTX: 116.35 (+0.42), BMRN: 86.64 (+2.73), GILD: 107.85 (+1.40), ALXN: 194.26 (+0.45)
Why BioMarin Pharmaceutical Inc. Roared 14% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 9:01AM CST
BMRN data by YCharts What: Shares of BioMarin Pharmaceutical , a biopharmaceutical company focused on developing therapies to treat rare and ultra-rare diseases and disorders, roared higher by 14% in October, based on data from S&P...
BMRN: 86.64 (+2.73)
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Tue Nov 04, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that Jean-Jacques Bienaime, Chief Executive Officer at BioMarin, will present at the Credit Suisse 2014 Healthcare Conference on Tuesday, November 11, 2014 at 1:30pm MT.
BMRN: 86.64 (+2.73)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 86.64 (+2.73), ISIS: 46.21 (+1.62), SGEN: 35.84 (-0.21), GILD: 107.87 (+1.42), SSYS: 104.19 (+1.12), HP: 86.10 (-0.60), REGN: 383.61 (+5.77), CELG: 107.66 (+1.21)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.98 (+0.83), GE: 26.48 (+0.07), BMRN: 86.64 (+2.73), IDXX: 146.16 (+1.00), GSK: 45.21 (+0.30), NVS: 92.48 (+0.72)
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:54AM CDT
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue?
BMRN: 86.64 (+2.73)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 110.23 (-2.54), MACK: 8.60 (-0.10), BMRN: 86.64 (+2.73), ILMN: 188.83 (+2.48)
The 5 Most Expensive Drugs in the World
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 26, 11:21AM CDT
Source: StockMonkeys.com via Flickr . Whether you're prepared for it or not, prescription drug prices remain on the rise within the United States. Overall medical cost inflation may be at a multi-decade low in the U.S., but that doesn't seem to...
MNK: 92.60 (+1.54), VRTX: 116.35 (+0.42), BMRN: 86.64 (+2.73), SHPG: 201.02 (+2.44), ALXN: 194.26 (+0.45)
After Yesterday's Rally of 8.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Oct 24, 4:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $75.40 to a high of $81.83. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high of $75.86 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 86.64 (+2.73)
BioMarin Q3 Loss Narrower than Expected, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:12PM CDT
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected third-quarter 2014 loss of 16 cents per share.
MDVN: 110.23 (-2.54), BMRN: 86.64 (+2.73), ILMN: 188.83 (+2.48), SNY: 46.30 (+0.61)
BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 7:38PM CDT
Every biotech dreams of having a blockbuster drug with annual sales higher than $1 billion. But ultra-orphan-drugmaker BioMarin Pharmaceuticals has a more realistic short-term goal: have $1 billion in sales for biotech's basket of five drugs. ...
BMRN: 86.64 (+2.73), SNY: 46.30 (+0.61)
BioMarin Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 3:02PM CDT
- VIMIZIM Sales Top $25 million in Second Full Quarter of Sales
BMRN: 86.64 (+2.73)
Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:30PM CDT
BioMarin is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 116.35 (+0.42), BMRN: 86.64 (+2.73), LGND: 53.91 (-0.03), TEVA: 58.07 (+0.37)
Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 86.64 (+2.73), ALNY: 99.19 (+3.35), SRPT: 16.13 (+0.01), SHPG: 201.02 (+2.44), NPSP: 26.81 (-0.68)
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 86.64 (+2.73), LXRX: 1.37 (+0.02), AMGN: 162.33 (+2.08), REGN: 383.61 (+5.77), EXEL: 1.76 (+0.02)
Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's "Roof Leaker" Stock
at The Street - Tue Oct 14, 9:13AM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
BMRN: 86.66 (+2.75)
BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
GlobeNewswire - Wed Oct 08, 7:35AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 23, at 4:30 p.m. ET to discuss third quarter 2014 financial results and provide a general business update.
BMRN: 86.66 (+2.75)
Recent News posted below.
Biomarin Pharmaceutical Inc BMRN other info.
http://investorshangout.com/Biomarin-Pharmace...MRN-53520/
BMRN Biomarin Pharmaceutical Inc Recent Headline News
Upgrade Alert for BioMarin Pharmaceutical (BMRN)
Comtex SmarTrend(R) - Mon Nov 10, 7:56AM CST
BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded from Neutral to Buy at Goldman Sachs today. The stock closed yesterday at $83.91 on volume of 727,000 shares, below average daily volume of 1.2 million. In the past 52 weeks, shares of BioMarin Pharmaceutical have traded between a low of $55.04 and a high of $86.80 and closed yesterday at $83.91, which is 52% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.8% while the 200-day MA has risen 0.4%.
BMRN: 86.64 (+2.73)
Shares of BMRN Up 13.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 05, 10:01AM CST
SmarTrend identified an Uptrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on October 21st, 2014 at $73.58. In approximately 2 weeks, BioMarin Pharmaceutical has returned 13.66% as of today's recent price of $83.63.
BMRN: 86.64 (+2.73)
Is This Trend Making Gilead Sciences, Inc. Worry?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 05, 9:40AM CST
Source: Gilead Sciences via Google Maps If you're sick, you expect your doctor to prescribe the appropriate treatment -- and if that treatment is a revolutionary medicine like Gilead 's Harvoni, you expect that your insurer will pay for it....
MNK: 92.60 (+1.54), VRTX: 116.35 (+0.42), BMRN: 86.64 (+2.73), GILD: 107.85 (+1.40), ALXN: 194.26 (+0.45)
Why BioMarin Pharmaceutical Inc. Roared 14% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 9:01AM CST
BMRN data by YCharts What: Shares of BioMarin Pharmaceutical , a biopharmaceutical company focused on developing therapies to treat rare and ultra-rare diseases and disorders, roared higher by 14% in October, based on data from S&P...
BMRN: 86.64 (+2.73)
Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2014 Healthcare Conference
GlobeNewswire - Tue Nov 04, 7:00AM CST
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), today announced that Jean-Jacques Bienaime, Chief Executive Officer at BioMarin, will present at the Credit Suisse 2014 Healthcare Conference on Tuesday, November 11, 2014 at 1:30pm MT.
BMRN: 86.64 (+2.73)
Cramer Sees HP Entering Sector as Trouble for 3-D Printing Stocks
at The Street - Mon Nov 03, 10:57AM CST
Even though HP won't start shipping its 3-D printing machines in bulk until 2016, it could be a problem for other 3-D printing companies.
BMRN: 86.64 (+2.73), ISIS: 46.21 (+1.62), SGEN: 35.84 (-0.21), GILD: 107.87 (+1.42), SSYS: 104.19 (+1.12), HP: 86.10 (-0.60), REGN: 383.61 (+5.77), CELG: 107.66 (+1.21)
Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 186.98 (+0.83), GE: 26.48 (+0.07), BMRN: 86.64 (+2.73), IDXX: 146.16 (+1.00), GSK: 45.21 (+0.30), NVS: 92.48 (+0.72)
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:54AM CDT
Can the Rally in BioMarin Pharmaceutical (BMRN) Shares Continue?
BMRN: 86.64 (+2.73)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 110.23 (-2.54), MACK: 8.60 (-0.10), BMRN: 86.64 (+2.73), ILMN: 188.83 (+2.48)
The 5 Most Expensive Drugs in the World
Sean Williams, The Motley Fool - Motley Fool - Sun Oct 26, 11:21AM CDT
Source: StockMonkeys.com via Flickr . Whether you're prepared for it or not, prescription drug prices remain on the rise within the United States. Overall medical cost inflation may be at a multi-decade low in the U.S., but that doesn't seem to...
MNK: 92.60 (+1.54), VRTX: 116.35 (+0.42), BMRN: 86.64 (+2.73), SHPG: 201.02 (+2.44), ALXN: 194.26 (+0.45)
After Yesterday's Rally of 8.03% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Oct 24, 4:47PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $75.40 to a high of $81.83. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high of $75.86 on volume of 2.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 86.64 (+2.73)
BioMarin Q3 Loss Narrower than Expected, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 12:12PM CDT
BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected third-quarter 2014 loss of 16 cents per share.
MDVN: 110.23 (-2.54), BMRN: 86.64 (+2.73), ILMN: 188.83 (+2.48), SNY: 46.30 (+0.61)
BioMarin Pharmaceutical Inc. Earnings: Striving to Be a Blockbuster Company
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 23, 7:38PM CDT
Every biotech dreams of having a blockbuster drug with annual sales higher than $1 billion. But ultra-orphan-drugmaker BioMarin Pharmaceuticals has a more realistic short-term goal: have $1 billion in sales for biotech's basket of five drugs. ...
BMRN: 86.64 (+2.73), SNY: 46.30 (+0.61)
BioMarin Announces Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 23, 3:02PM CDT
- VIMIZIM Sales Top $25 million in Second Full Quarter of Sales
BMRN: 86.64 (+2.73)
Will BioMarin (BMRN) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 4:30PM CDT
BioMarin is scheduled to report third-quarter 2014 results on Oct 23.
VRTX: 116.35 (+0.42), BMRN: 86.64 (+2.73), LGND: 53.91 (-0.03), TEVA: 58.07 (+0.37)
Some Potential Targets for Shire to Buy With $1.6B in Free Money
at The Street - Tue Oct 21, 8:29AM CDT
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?
BMRN: 86.64 (+2.73), ALNY: 99.19 (+3.35), SRPT: 16.13 (+0.01), SHPG: 201.02 (+2.44), NPSP: 26.81 (-0.68)
Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma
PR Newswire - Mon Oct 20, 8:00AM CDT
Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, October 17, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,380.41, up 1.63% and the NASDAQ Composite closed at 4,258.44, up 0.97%. The S&P 500 finished the session 1.29% higher at 1,886.76. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 707.88, up 1.61%, with the index advancing 10.21% on YTD basis. Register for your complimentary reports on these five stocks at:
BMRN: 86.64 (+2.73), LXRX: 1.37 (+0.02), AMGN: 162.33 (+2.08), REGN: 383.61 (+5.77), EXEL: 1.76 (+0.02)
Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's "Roof Leaker" Stock
at The Street - Tue Oct 14, 9:13AM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
BMRN: 86.66 (+2.75)
BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET
GlobeNewswire - Wed Oct 08, 7:35AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 23, at 4:30 p.m. ET to discuss third quarter 2014 financial results and provide a general business update.
BMRN: 86.66 (+2.75)
(0)
(0)